SBIR/STTR Research Award

Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance

Award identifier 22a54bed6ee664f0d16b7a539995e87317108016581ea50ba500f8fcdb9f02ceAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,541,693

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ELYSIUM THERAPEUTICS, INC.
Proposal award date
2015-03-01
Contract end date
2017-02-28
UEI
CQ2LJLATAKH9
Solicitation number
DA14-013
Topic code
NIDA

Research abstract

DESCRIPTION The abuse of prescription drugs is the fastest growing drug problem in the United States and reducing such abuse is a national priority While one of the most prevalent routes of abuse for opioid medicines is the oral route current formulation and molecular based technologies are primarily designed to resist abuse via non oral routes e g inhalation and injection Consequently these approaches fail to adequately address oral abuse and overdose i e co ingestion of multiple pills and can be easily thwarted by straightforward extraction techniques To address the nationandapos s prescription drug misuse abuse and overdose epidemics comprehensive robust abuse resistance technologies need to be developed and ideally applied to all prescription opioid drugs To that end we propose to qualify at least one product candidate for IND enabling studies from a unique class of proprietary molecules designed to provide effective opioid based pain relief with unprecedented protection from all routes of abuse We are applying for Fast Track because NIDA program officials assured us that our proposed project is an excellent Fast Track candidate based on Compelling in vitro and in vivo data from studies led by our Principal Investigator demonstrate feasibility Current formulation based technologies do not effectively address oral misuse abuse and overdose and Key stakeholders i e potential large pharmaceutical partners for development and commercialization key opinion leaders prescribing physicians and patients have expressed strong interest in our technology PUBLIC HEALTH RELEVANCE The entwined epidemics of prescription opioid abuse and undertreated pain have given rise to the need for pain therapies that are less likely to be abused While one of the most prevalent routes of abuse for opioid medicines is the oral route no technologies have been developed to protect against overdose from the co ingestion of multiple pills andquot oral overdoseandquot Elysium has discovered a unique class of proprietary molecules designed to provide effective opioid based pain relief with unprecedented protection from all routes of abuse

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2014–2018). Reported award amounts total $6,722,094. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.